Veradermics (MANE) Capital Expenditures (2025 - 2026)
Veradermics' (MANE) quarterly Capital Expenditures came in at $174000.0 in Q1 2026, up 815.79% YoY from $19000.0 in Q1 2025, and up 815.79% on a QoQ basis from $19000.0 in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Capital Expenditures (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Capital Expenditures data on file, last reported at $174000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | 80,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Mar 31, 2026 | 174,000.00 |
| Mar 31, 2025 | 19,000.00 |